Profound Medical (TSE:PRN) Trading Up 4.3% – Should You Buy?

Profound Medical Corp. (TSE:PRN) shares were up 4.3% during trading on Tuesday . The stock traded as high as C$9.60 and last traded at C$9.56. Approximately 11,300 shares traded hands during trading, a decline of 33% from the average daily volume of 16,826 shares. The stock had previously closed at C$9.17.

Profound Medical Trading Down 0.4%

The company’s 50 day moving average price is C$9.32 and its 200 day moving average price is C$9.48. The company has a market cap of C$338.67 million, a price-to-earnings ratio of -7.52 and a beta of 1.26. The company has a debt-to-equity ratio of 12.56, a quick ratio of 14.98 and a current ratio of 6.56.

Profound Medical (TSE:PRN) last announced its quarterly earnings results on Thursday, May 7th. The company reported C$0.26 EPS for the quarter. The company had revenue of C$7.42 million for the quarter. Profound Medical had a negative net margin of 206.94% and a negative return on equity of 78.75%. Research analysts anticipate that Profound Medical Corp. will post -1.9000001 EPS for the current year.

Insider Activity

In other news, Director Dr. Arun Menawat acquired 20,000 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The stock was acquired at an average cost of C$6.96 per share, with a total value of C$139,200.00. Following the acquisition, the director owned 658,660 shares in the company, valued at approximately C$4,584,273.60. This represents a 3.13% increase in their ownership of the stock. Corporate insiders own 8.62% of the company’s stock.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.